UK and EU Biopharma Outlook: What to Expect in 2024

March 13, 2024
Event details
March 13, 2024
4:00 – 5:00 pm GMT Standard Time

Event summary

Cooley partners Simon Amies, Tom Goodman, Frances Stocks Allen, and Courtney Thorne discussed what 2024 has in store for UK and European Union biopharma companies. Topics included UK and European perspectives on trends in funding, M&A and pharma partnering, as well as covering the status of US capital markets, whether the initial public offering (IPO) markets will finally reopen, and venture capital trends in demand for UK and European companies.

Details and registration

This content is provided for general informational purposes only, and your access or use of the content does not create an attorney-client relationship between you or your organization and Cooley LLP, Cooley (UK) LLP, or any other affiliated practice or entity (collectively referred to as “Cooley”). By accessing this content, you agree that the information provided does not constitute legal or other professional advice. This content is not a substitute for obtaining legal advice from a qualified attorney licensed in your jurisdiction and you should not act or refrain from acting based on this content. This content may be changed without notice. It is not guaranteed to be complete, correct or up to date, and it may not reflect the most current legal developments. Prior results do not guarantee a similar outcome. Do not send any confidential information to Cooley, as we do not have any duty to keep any information you provide to us confidential. This content may be considered Attorney Advertising and is subject to our legal notices.